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Therapy-related myelodysplasia or acute myeloid leukemia
(t-MDS/AML) is a major cause of non-relapse mortality in patients
treated for Hodgkin lymphoma (HL) or non-Hodgkin lymphoma
(NHL).
1 t-MDS/AML is associated with exposure to alkylating
agents and topoisomerase II inhibitors. The DNA-damaging events
caused by these agents initiate apoptosis required for antineo-
plastic activity; occasionally, imperfect repair of chromosomal
damage results in chromosomal aberrations, leading to leukemo-
genesis.
The inter-individual variability in the risk of t-MDS/AML for any
given exposure to genotoxic agents suggests the role of genetic
susceptibility. In addition, t-MDS/AML shares morphological and
genetic similarity with de novo MDS/AML,
2 suggesting that
therapy-related and de novo MDS/AML may share genetic
susceptibility loci. Previous studies have been largely inconclusive,
primarily because of the focus on single genes.
3,4 In the few
studies where multiple genes were examined simultaneously,
individuals with more than one risk variant were at higher risk.
5,6
We hypothesized that genetic variations encoded in key genes in
the pathways of drug metabolism, apoptosis, DNA synthesis,
methylation and repair, as well as genes involved in de novo AML,
7
could potentially contribute to the risk of t-MDS/AML. Using both
genotype and gene expression analyses, we investigated whether
individual genetic variability in these pathways modify the risk of
t-MDS/AML in patients with HL or NHL exposed to genotoxic
agents (Figure 1). We also tested for synergy between apoptosis
and other hypothesized pathways.
Patients treated with conventional therapy or autologous
hematopoietic cell transplantation (aHCT) for HL or NHL formed
the sampling frame for this case-control study. Cases (n¼49)
consisted of patients who subsequently developed t-MDS/AML.
Controls (n¼49) were drawn from the same sampling frame, did
not have t-MDS/AML and were matched to cases using the
following criteria: primary diagnosis (HL or NHL), age at primary
diagnosis and year of primary diagnosis, length of follow-up from
diagnosis (longer for controls) and genetic ancestry. To further
reﬁne matching on genetic ancestry, we used STRUCTURE 2.0
(ref. 8)
to estimate ancestry composition of study subjects based on 51
informative markers (AIM)
9 (Supplementary Methods and Supple-
mentary Table 1). Gene expression patterns were studied in
hematopoietic stem/progenitor cells (HSC) from peripheral blood
stem cell (PBSC) autografts from a subset of 12 NHL cases and 22
matched controls. The Human Subjects Protection Committee at
City of Hope approved the protocol. Informed consent was
provided according to the Declaration of Helsinki. For each study
participant, cumulative therapeutic exposures were calculated, as
detailed in the Supplementary Methods. Demographic and clinical
characteristics of the study subjects are summarized in Supple-
mentary Table 2.
We genotyped 29 SNPs and 2 deletion polymorphisms for 23
candidate genes (Supplementary Table 3). Association between
individual polymorphisms and t-MDS/AML was analyzed using
exact conditional logistic regression, adjusted for gender, treat-
ment modality (conventional therapy vs aHCT) and cumulative
exposure to alkylating agents and topoisomerase II inhibitors. We
observed a higher risk for t-MDS/AML among patients with
deletion of GSTM1, the Pro allele of P72R in TP53, the T allele
of CYP1A1*2A, and the T allele of rs6030469 of PTPRT (Table 1).
None of these associations withstood Bonferroni adjustment for
multiple comparisons.
TP53 modulates DNA repair and apoptosis upon DNA damage.
A common germline polymorphism of TP53, P72R, produces
a proline to arginine change that enhances apoptotic activity
15-fold. We used likelihood ratio tests with permutations implemen-
ted in UNPHASED
10 to explore unadjusted gene--gene interaction
between P72R in TP53 and all polymorphisms in other candidate
genes. A signiﬁcant interaction between P72R and C677T, a
coding SNP in MTHFR, was detected and remained signiﬁcant
after correction for multiple testing using 10000 permutations
(adjusted Pinteraction¼0.048). This interaction was conﬁrmed after
adjustment for therapeutic exposures (Table 1). The homozygous
T allele of C677T increased the risk 71-fold (P¼0.0059) when
combined with the Pro carrier of P72R (conferring decreased
apoptotic activity) compared with its combination with homo-
zygous Arg. We also detected an interaction between P72R and
another coding SNP, A1298C, in MTHFR (Table 1). The homozygous
A allele of A1298C increased the risk 33-fold (P¼0.0005) when
combined with the Pro carrier of P72R compared with its
combination with homozygous Arg in the adjusted analysis.
Figure 1. Candidate genes in the biological pathways implicated in
the pathogenesis of t-MDS/AML.
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www.nature.com/bcjWe then examined expression levels of the 23 candidate genes
using Affymetrix HG U133 plus 2.0 array data procured from an
independent study that studied gene-expression proﬁles in
CD34þ HSCs
11 to detect differential expression between cases
and controls, adjusted for age at aHCT, gender and therapeutic
exposures, using a general linear model implemented in R. In total,
10 genes were differentially expressed between cases and
controls (Supplementary Table 4). This represents a signiﬁcant
enrichment (P¼0.0025) compared with a random draw of
23 genes from a whole genome of 20722 genes interrogated
on the U133 Plus 2 array. Signals (Po0.05) were detected for
TP53 and genes involved in drug metabolism (CYP3A4, GSTM1,
GSTP1 and GSTT1), DNA repair (XRCC1, XRCC2 and MTHFR), and
de novo AML (NMNAT2 and LAMC2). Expression level for TP53
was much lower in cases. Also, as hypothesized, expression of
genes was observed at much lower level for the three detoxiﬁca-
Table 1. Genetic susceptibility and risk of t-MDS- - -association studies and gene- -gene interaction
Case/Control Unadjusted Adjusted
a
OR (95% CI) Pexact OR (95% CI) Pexact
Association studies of individual polymorphisms
GSTM1, deletion 0.091 0.057
Ins/Ins 2/8 1 1
Ins/Del 24/18 7.38 (0.92- -339) 0.065 11.36 (1.03- -679.9) 0.046
Del/Del 22/23 5.98 (0.70- -283) 0.14 9.47 (0.86- -572.0) 0.076
GSTM1, deletion 0.070 0.033
Ins/Ins 2/8 1 1
Ins/Del or Del/Del 46/41 7.00 (0.90- -315.5) 0.070 11.24 (1.05- -666.0) 0.043
CYP1A1*2A 0.053 0.0089
C/C 0/3 1 1
C/T 9/13 2.89 (0.29- -N) 0.39 1.75 (0.11- -N) 0.69
T/T 40/33 6.77 (0.66- -N) 0.11 8.75 (0.61- -N) 0.11
CYP1A1*2A 0.092 0.014
C/C or C/T 9/16 1 1
T/T 40/33 3.33 (0.86- -18.85) 0.092 9.99 (1.25- -473.5) 0.023
TP53, P72R 0.31 0.046
Arg/Arg 22/30 1 1
Pro/Arg 21/14 1.96 (0.78- -5.31) 0.18 5.33 (1.16- -40.71) 0.026
Pro/Pro 6/5 1.63 (0.38- -7.43) 0.65 2.35 (0.37- -19.06) 0.49
TP53, P72R 0.17 0.039
Arg/Arg 22/30 1 1
Pro/Arg or Pro/Pro 27/19 1.89 (0.80- -4.81) 0.17 4.05 (1.06- -22.93) 0.038
PTPRT, rs6030469 0.057 0.030
G/G 29/36 1 1
G/T 9/2 3.68 (0.97- -20.47) 0.057 8.92 (1.05- -445.0) 0.043
Synergistic effect of TP53 and MTHFR
MTHFR C677T 0.55 1.00
T/T 7/4 1 1
T/C or C/C 42/45 0.57 (0.12- -2.25) 0.55 0.98 (0.18- -5.19) 1.00
TP53 P72R MTHFR C677T 0.0091
b 0.036
b
P72R C677T 0.0060 0.0025
Arg/Arg T/T 0/4 1 1
Arg/Arg T/C or C/C 22/26 4.99 (0.61- -N) 0.15 7.95 (0.82- -N) 0.076
Arg/Pro or Pro/Pro T/C or C/C 20/19 4.99 (0.61- -N) 0.15 12.65 (1.27- -N) 0.029
Arg/Pro or Pro/Pro T/T 7/0 30.46 (2.44- -N) 0.0069 70.95 (3.44- -N) 0.0059
MTHFR A1298C 1.00 0.60
A/A 24/23 1 1
A/C or C/C 25/26 0.90 (0.32- -2.46) 1.00 0.73 (0.21- -2.43) 0.76
TP53 P72R MTHFR A1298C 0.0045
b 0.0035
b
P72R A1298C 0.0052 0.0006
Arg/Arg A/A 8/19 1 1
Arg/Arg A/C or C/C 14/11 5.40 (0.96- -44.7) 0.057 8.73 (0.70- -609) 0.124
Arg/Pro or Pro/Pro A/C or C/C 11/15 1.80 (0.34- -12.1) 0.663 1.85 (0.14- -33.4) 0.977
Arg/Pro or Pro/Pro A/A 16/4 9.11 (1.89- -73.6) 0.0021 33.21 (2.91- -N) 0.0005
Abbreviations: CI, conﬁdence interval; OR, odds ratio; t-MDS, therapy-related myelodysplasia.
aAdjusted for gender, aHCT (autologous hematopoietic
cell transplantation; because of incomplete matching for 13 cases), alkylating agent score and topoisomerase inhibitor score. Not adjusted for multiple
comparisons. Bold if o0.05 on genotype test.
bPinteraction between SNPs in TP53 and MTHFR.B o l di fo0.05.
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drug activation gene, CYP3A4, was signiﬁcantly higher in cases.
Relative expression levels measured by microarray were evaluated
using TaqMan-based reverse transcribed quantitative PCR (RT-qPCR)
gene-expression assays (Applied Biosystems) in 17 subjects for
GSTM1 (Hs01683722_gH), TP53 (Hs1034249_m1) and MTHFR
(Hs0015560_m1) referenced on ACTB (Hs99999903_m1); correla-
tions were found to be statistically signiﬁcant for GSTM1 (R
2¼0.50,
P¼0.0015) and TP53 (R
2¼0.24, P¼0.044). Gene-expression levels
of GSTM1 and GSTT1 were signiﬁcantly correlated with deletion
polymorphisms (Po0.0031) in the respective genes after adjusting
for multiple comparisons.
We observed associations between t-MDS/AML and genes
responsible for drug metabolism supported by both genotyping
and expression studies, underscoring the mechanistic relationship
between t-MDS/AML and therapeutic exposures. Results were
compatible with increased genotoxic stress resulting from
enhanced drug activation and disrupted drug clearance among
cases. Previous meta-analyses of case-control studies have
demonstrated a modest increase in risk of de novo MDS/AML
associated with the null genotypes of drug-detoxiﬁcation genes,
GSTM1 and GSTT1, and a trend for overrepresentation for 105Val
allele of GSTP1.
12 Thus, we conﬁrmed an increased risk for
t-MDS/AML associated with GSTM1 homozygous deletion, and
detected signiﬁcantly lower gene-expression level in cases for all
three genes (GSTM1, GSTT1 and GSTP1). CYP3A4 encodes a hepatic
phase I P450 protein involved in activation of cyclophosphamide
and some anthracycline agents. In the current study, CYP3A4
expression in the CD34þ cells was signiﬁcantly higher in cases.
We observed a higher risk for t-MDS/AML among Pro carriers of
P72R in the genotyping study accompanied by a signiﬁcantly
lower expression level of TP53 in cases. More importantly, we
detected a synergistic effect between TP53 and MTHFR. MTHFR
directs 5, 10-methylene tetrahydrofolate toward methionine
synthesis and conversion to the universal methyl donor,
S-adenosylmethionine, at the expense of pyrimidine synthesis
that is required for DNA synthesis and repair. Two polymorphisms,
C677T and A1298C, have been associated with reduced enzyme
activity.
13 Both SNPs were found to interact with P72R in
increasing the risk of t-MDS/AML. MTHFR has been extensively
investigated for susceptibility to cancer because of its key role in
intracellular folate homeostasis and metabolism that are funda-
mental to DNA synthesis, repair and methylation. Meta-analyses
has shown that the T allele of C677T polymorphism and the A
allele of A1298C are associated with gastric and colorectal cancers,
respectively.
14 Expression of both TP53 and MTHFR was signiﬁ-
cantly lower in cases compared with controls, supporting their role
in t-MDS/AML development. We proposed a model to explain the
interaction between TP53 and MTHFR (Supplementary Figure 1).
Reduced MTHFR activity is associated with chromosomal aberra-
tions during DNA repair.
15 When combined with higher TP53
activity, it would normally result in efﬁcient clearance of damaged
cells through apoptosis. However, when combined with less-
efﬁcient TP53, it would result in accumulation of progenitor cells
with chromosomal damage and increase the risk of t-MDS/AML.
On the other hand, with normal MTHFR activity to support DNA
repair, allele variants of TP53 do not have an impact on t-MDS/
AML development, because efﬁcient DNA repair would maximize
DNA recovery and minimize the risk of chromosomal aberrations.
The current study is the ﬁrst to report a synergistic impact of SNPs
in MTHFR and TP53 on t-MDS/AML, however, the observation
requires conﬁrmation.
The study was limited by a relatively small sample size; the rarity
of t-MDS/AML precluded a large-scale study. However, the study
was strengthened by the combined use of genotyping and gene-
expression analyses with detailed information regarding thera-
peutic exposures, allowing for the more robust (and hence
clinically relevant) observations to emerge. Supporting evidence
from both genotyping and expression analyses for GSTM1, TP53
and MTHFR suggests their contribution to t-MDS/AML as germ-line
genetic factors. In summary, we demonstrate that the risk of
t-MDS/AML is related to the individual capacity of drug metabolism,
apoptosis and DNA synthesis. These observations not only will
further our understanding of the pathogenesis of t-MDS/AML but
also, when conﬁrmed in independent studies, will help identify
those at the highest risk, setting the stage for targeted surveillance
and/or interventions.
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